Technical Analysis for NBIX - Neurocrine Biosciences, Inc.

Grade Last Price % Change Price Change
B 96.5 0.81% 0.78
NBIX closed up 0.81 percent on Friday, September 17, 2021, on 2.07 times normal volume.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Up
Historical NBIX trend table...

Date Alert Name Type % Chg
20 DMA Support Bullish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
BB Squeeze Started Range Contraction 0.00%
20 DMA Support Bullish 0.81%
50 DMA Support Bullish 0.81%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.81%
20 DMA Support Bullish 0.17%
Outside Day Range Expansion 0.17%
200 DMA Resistance Bearish -0.21%
Older End-of-Day Signals for NBIX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Neurocrine Biosciences, Inc. Description

Neurocrine Biosciences, Inc. engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. It develops drugs for endometriosis, tardive dyskinesia, uterine fibroids, stress-related disorders, pain, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders. The company's products in clinical development include Elagolix, a Phase III drug for endometriosis; Vesicular Monoamine Transporter 2 Inhibitor (VMAT2), a Phase II drug for movement disorders; CRF2 Peptide Agonist, a Phase II drug for cardiovascular diseases; CRF1 Antagonist, a Phase II drug for stress-related disorders; and Elagolix, a Phase II drug for uterine fibroids. Its research programs comprise G Protein-Coupled Receptor 119 (GPR119) for type II diabetes; VMAT2 for schizophrenia; gonadotropin-releasing hormone (GnRH) Antagonists for men's and women's health, and oncology; Antiepileptic Drugs for epilepsy, essential tremor, and pain; and G Protein-Coupled Receptors for other conditions. The company has collaborations with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women's and men's health; Boehringer Ingelheim International GmbH to research, develop, and commercialize small molecule GPR119 agonists for the treatment of Type II diabetes and other indications; and Dainippon Sumitomo Pharma Co. Ltd. to develop and commercialize indiplon in Japan. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Clinical Development Pain Diabetes Disorders Cardiovascular Disease Schizophrenia Alcohols Epilepsy Hormones Vascular Diseases Ethers Cardiovascular Diseases Related Diseases Movement Disorders Related Disease Related Disorders Transporter Boehringer Ingelheim I Diabetes Insomnia Endometriosis Fibroids Ii Diabetes Dyskinesia Essential Tremor Gnrh Antagonists Pyrimidines Uterine Fibroid Uterine Fibroids Gonadotropin Releasing Hormone Antagonist Neurocrine Biosciences

Is NBIX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 120.27
52 Week Low 84.85
Average Volume 608,107
200-Day Moving Average 98.19
50-Day Moving Average 93.98
20-Day Moving Average 94.96
10-Day Moving Average 95.54
Average True Range 2.59
ADX 14.64
+DI 19.69
-DI 16.89
Chandelier Exit (Long, 3 ATRs) 90.44
Chandelier Exit (Short, 3 ATRs) 97.12
Upper Bollinger Bands 97.75
Lower Bollinger Band 92.18
Percent B (%b) 0.78
BandWidth 5.87
MACD Line 0.78
MACD Signal Line 0.62
MACD Histogram 0.16
Fundamentals Value
Market Cap 9.02 Billion
Num Shares 93.4 Million
EPS 0.96
Price-to-Earnings (P/E) Ratio 100.21
Price-to-Sales 8.97
Price-to-Book 11.10
PEG Ratio 1.87
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 100.71
Resistance 3 (R3) 100.39 98.67 100.01
Resistance 2 (R2) 98.67 97.60 98.83 99.77
Resistance 1 (R1) 97.59 96.94 98.13 97.90 99.54
Pivot Point 95.87 95.87 96.14 96.02 95.87
Support 1 (S1) 94.78 94.79 95.32 95.10 93.46
Support 2 (S2) 93.06 94.13 93.22 93.23
Support 3 (S3) 91.98 93.06 92.99
Support 4 (S4) 92.29